Last reviewed · How we verify

Tramadol/Diclofenac 50/50 — Competitive Intelligence Brief

Tramadol/Diclofenac 50/50 (Tramadol/Diclofenac 50/50) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Opioid analgesic/NSAID. Area: Pain management.

phase 3 Opioid analgesic/NSAID Opioid receptors/COX enzymes Pain management Small molecule Live · refreshed every 30 min

Target snapshot

Tramadol/Diclofenac 50/50 (Tramadol/Diclofenac 50/50) — Grünenthal GmbH. Tramadol is a centrally acting opioid analgesic, while diclofenac is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits prostaglandin synthesis.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Tramadol/Diclofenac 50/50 TARGET Tramadol/Diclofenac 50/50 Grünenthal GmbH phase 3 Opioid analgesic/NSAID Opioid receptors/COX enzymes
Tramadol/Diclofenac 25/25 Tramadol/Diclofenac 25/25 Grünenthal GmbH phase 3 Opioid analgesic/NSAID Opioid receptors/COX enzymes

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Opioid analgesic/NSAID class)

  1. Grünenthal GmbH · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Tramadol/Diclofenac 50/50 — Competitive Intelligence Brief. https://druglandscape.com/ci/tramadol-diclofenac-50-50. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: